Therapeutic Drug Monitoring of Vancomycin Concentrations for the Management of Bone and Joint Infections: An urgent need

• Published in: Tropical medicine and infectious disease Vol. 8; no. 2; pp. 1 - 10
• Main Authors: Rio-No, Laura, Sorli, Luisa, Arderiu-Formenti, Alba, De Antonio, Marta, Martorell, Lucas, Subirana, Isaac, Puig, Lluis, Alier, Albert, Gómez-Junyent, Joan, Pérez-Prieto, Daniel, Luque, Sonia
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland MDPI 01-02-2023; MDPI AG
• Subjects: Antibiotics; bone and joint infections; Ceftaroline; Clinical outcomes; Comparative analysis; dosage regimens; Drug dosages; Drug monitoring; Evaluation; Gram-positive bacteria; Health aspects; Infections; Joints; Laboratories; Methicillin; nephrotoxicity; Nephrotoxicology; Pharmacokinetics; Prostheses; Regression analysis; Staphylococcus infections; Therapeutic drug monitoring; Vancomycin; Spain; United States > US; Chicago Illinois; pharmacokinetics; vancomycin; dosage regimens; nephrotoxicity; bone and joint infections; therapeutic drug monitoring
• ISSN: 2414-6366; 2414-6366
• DOI: 10.3390/tropicalmed8020113

Vancomycin is used for the treatment of bone and joint infections (BJI), but scarce information is available about its pharmacokinetic/pharmacodynamic (PK/PD) characteristics. We aimed to identify the risk factors associated with the non-achievement of an optimal PK/PD target in the first therapeutic drug monitoring (TDM). Methods: A retrospective study was conducted in a tertiary hospital from January 2020 to January 2022. Patients with BJI and TDM of vancomycin on day 2 of treatment were included. Initial vancomycin fixed doses (1 g every 8 h or 12 h) was decided by the responsible doctors. According to TDM results, dosage adjustments were performed. An AUC24h/MIC < 400 mg x h/L, between 400 and 600 mg x h/L and >600 mg x h/L, were defined as suboptimal, optimal and supratherapeutic, respectively. Patients were grouped into these three categories. Demographic, clinical and PK characteristics were compared between groups. Nephrotoxicity at the end of treatment was assessed. Results: A total of 94 patients were included: 22 (23.4%), 42 (44.7%) and 30 (31.9%) presented an infratherapeutic, optimal and supratherapeutic PK/PD targets, respectively. A younger age and initial vancomycin dose <40 mg/kg/day were predictive factors for achieving a suboptimal PK/PD target, while older age, higher serum-creatinine and dose >40 mg/kg/day were associated with overexposure. The nephrotoxicity rate was 22.7%. More than 50% of patients did not achieve an optimal PK/PD. Considering age, baseline serum-creatinine and body weight, TDM is required to readily achieve an optimal and safe exposure.